In biology, there’s not been the same push for an integrated digital platform to design, manage, automate and analyze the ever more complex process of life science. In fact, biology is well-known for its reliance on repetitive manual tasks which require scientists to be physically pipetting or cell-culturing in the fume hood; for its lack of reproducible results when experiments are conducted and recorded in such a non-standardised manner; and for its "brute force" trial-and-error approach to drug discovery.
Using Benchling, researchers can design, record, analyze, share, and constantly update data in the cloud. Generated data can be shared with members of a team, and other scientists around the world. Benchling has, on average, increased scientist productivity by up 30 to 50 percent, automating organizational tasks and reducing experiment duplication, according to feedback from users, says MIT co-founder Saji Wickramasekara. “It really impacts the productivity and day-to-day life of researchers,” he says.
DNA sequencing was still very expensive and rare at the time, but Mangubat and her cofounders at Spiral Genetics anticipated a day when the cost of sequencing a genome would drop enough to allow scientists to sequence hundreds of thousands or millions of human genomes, whole populations, and compare them to learn about disease. To analyze such a volume of data, with the technology of the time, would have been prohibitively difficult and time-consuming, Mangubat predicted. Her company aimed to leverage cloud-based computing to crunch those huge gene sets, taking a fraction of the time.
As we enter 2020, investors, scientists and thought leaders are increasingly emphasizing the need to evolve the original concept of Femtech beyond reproductive health and what concerns the female reproductive organs, to that of a lenses through which we look into health issues that impact us differently, especially those that disproportionately affect women, such as Alzheimer’s or immunodeficiencies. The Femtech movement is progressing into a more intersectional territory, where otherwise non-female exclusive issues meet the specific needs of the female biology.
OnRamp Bioinformatics, Inc., a genomics company providing the premier scientist-focused data analysis platform, and Advaita BioInformatics, a leader in personalized medicine and interpretation of Next-Gen Sequencing data, announced they have partnered to provide a comprehensive research experience from sample to interpretation with a seamless hand-off between systems.